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A B S T R A C T
Cardiac myosin binding protein-C (cMyBP-C) phosphorylation is essential for normal heart function and protects
the heart from ischemia-reperfusion (I/R) injury. It is known that protein kinase-A (PKA)-mediated phosphor-
ylation of cMyBP-C prevents I/R-dependent proteolysis, whereas dephosphorylation of cMyBP-C at PKA sites
correlates with its degradation. While sites on cMyBP-C associated with phosphorylation and proteolysis co-
localize, the mechanisms that link cMyBP-C phosphorylation and proteolysis during cardioprotection are not
well understood. Therefore, we aimed to determine if abrogation of cMyBP-C proteolysis in association with
calpain, a calcium-activated protease, confers cardioprotection during I/R injury. Calpain is activated in both
human ischemic heart samples and ischemic mouse myocardium where cMyBP-C is dephosphorylated and
undergoes proteolysis. Moreover, cMyBP-C is a substrate for calpain proteolysis and cleaved by calpain at re-
sidues 272-TSLAGAGRR-280, a domain termed as the calpain-target site (CTS). Cardiac-speciﬁc transgenic (Tg)
mice in which the CTS motif was ablated were bred into a cMyBP-C null background. These Tg mice were
conclusively shown to possess a normal basal structure and function by analysis of histology, electron micro-
scopy, immunoﬂuorescence microscopy, Q-space MRI of tissue architecture, echocardiography, and hemody-
namics. However, the genetic ablation of the CTS motif conferred resistance to calpain-mediated proteolysis of
cMyBP-C. Following I/R injury, the loss of the CTS reduced infarct size compared to non-transgenic controls.
Collectively, these ﬁndings demonstrate the physiological signiﬁcance of calpain-targeted cMyBP-C proteolysis
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and provide a rationale for studying inhibition of calpain-mediated proteolysis of cMyBP-C as a therapeutic
target for cardioprotection.
1. Introduction
Ischemic heart disease is a leading global health concern that aﬀects
5 million people annually [1–3]. Experimental models featuring cardiac
ischemia-reperfusion (I/R) injury have been used to study a variety of
detrimental eﬀects, ranging from cell necrosis to ﬁbrotic scarring [4–7],
hypoxia [8,9], apoptosis [10–12], and protein degradation. Cardiac
sarcomere proteins have been identiﬁed as speciﬁc substrates for post-
ischemic proteolysis [13]. Following ischemia, multiple proteins and
pathways associated with the cardiac sarcomere, including cardiac
myosin binding protein-C (cMyBP-C), cardiac troponin I, and myosin
light chain [13–15], are subject to post-translational modiﬁcation and
degradation. In particular, proteolysis of cMyBP-C during ischemia
leads to impaired function in cells that survive I/R injury [15,16].
Cardiac MyBP-C is a thick and thin myoﬁlament-interacting protein
involved in regulating sarcomere structure and function in the heart
[17]. Mutations that impair this protein's function have been linked to
familial hypertrophic cardiomyopathy in> 60 million people world-
wide [18–20], highlighting the clinical urgency of fully elucidating the
function of cMyBP-C [17]. Previously, we showed that phosphorylation
of cMyBP-C by protein kinase A (PKA) regulates myocardial function
[21,22] and confers resistance to proteolysis and protection of cardiac
tissue against ischemia-reperfusion (I/R) injury [22,23]. Cardiac MyBP-
C is phosphorylated under physiological conditions by an array of sig-
naling kinases, including PKA, protein kinase C, protein kinase D, ri-
bosomal S6 kinase, glycogen synthase kinase 3β [24], and calcium-
calmodulin-activated kinase II (CaMKII) [25]. Calcium activation of
CaMKII can inﬂuence contractility by phosphorylation of cMyBP-C
serine (S) 282 [25,26]. We have shown that phosphorylation of S282 is
required for the subsequent phosphorylation of cMyBP-C and that these
signaling events are required for many of the regulatory functions of
cMyBP-C [21,27,28].
Reduced phosphorylation of cMyBP-C has been observed in mouse
models of I/R injury [15], pathological hypertrophy [29], heart failure
[30], cytoskeletal muscle LIM protein-knockout mice [21], myocardial
stunning [15], as well as human cases of atrial ﬁbrillation [31] and
heart failure [32,33]. Such dephosphorylation is accompanied by pro-
teolysis of cMyBP-C in association with thick ﬁlament disruption, loss of
contractile regulation, and contractile dysfunction [15,22]. Transgenic
(Tg) mice expressing cMyBP-C with phosphorylatable serine residues
mutated to phosphomimetic aspartic acids have reduced cMyBP-C
proteolysis following I/R injury [22]. We previously reported that
cMyBP-C proteolysis occurs between residues 271 and 272, located in
the phosphorylatable M-domain, and results in the generation of a
40 kDa N′-terminal fragment (residues 1–271) that includes key reg-
ulatory sites [34,35]. In addition to impaired regulatory function fol-
lowing proteolysis, the cMyBP-C 40 kDa fragment has been shown to
directly impair contractility in adult rat [14] and human [36] cardio-
myocytes. Furthermore, the expression of this fragment leads to heart
failure in vivo [34].
We established herein the role of calpain proteases in degrading
cMyBP-C and generating the 40 kDa fragment in human and mouse
ischemic myocardium. Moreover, we speciﬁcally characterized a mouse
model that expresses a mutant cMyBP-C with the calpain target site
(CTS) removed [37]. While this model showed no evidence of structural
or functional impairment under normal conditions, we demonstrated
that speciﬁc abrogation of calpain-mediated proteolysis of cMyBP-C in
the ΔCTS model can oﬀer a signiﬁcant degree of cardioprotection
during I/R injury in vivo. Under physiological conditions, these data
suggest that preventing proteolysis of full-length cMyBP-C may result in
the preservation of myocardial tissue and provide cardioprotection
during I/R injury.
2. Methods
2.1. Human heart samples
LV tissue samples were collected from nine non-failing human
hearts that were not used for transplantation (5 males, 4 females, mean
age 45 ± 3 years) and eight patients who had a myocardial infarction
(7 males, 1 female, mean age 52 ± 3 years). The Institutional Review
Boards at the University of Szeged, Hungary, Ohio State University,
Columbus, OH, and Loyola University Chicago, Maywood, IL, USA,
approved this study. Human hearts were obtained immediately (within
seconds) post-explanation and ﬂushed with a cardioplegic solution, as
described previously [38,39]. The explanted hearts were quickly
(within 10–30min) transferred to the laboratory in a cold (~4 °C)
cardioplegic solution containing (in mM) 110 NaCl, 16 KCL, 16 MgCl2,
10 NaHCO3, and 0.5 CaCl2. Upon arrival in the laboratory, samples
were ﬂash-frozen and stored in −80 °C freezers. All hearts were pro-
cured and treated with identical protocols, solutions, and timing, irre-
spective of source. Human tissue experimentation conformed to the
Declaration of Helsinki. Informed consent was acquired from cardiac
transplant patients, while non-transplantable donor hearts were ac-
quired in identical fashion in the operating room in collaboration with
Lifeline of Ohio Organ Procurement.
2.2. Transgenic mouse models
All mouse models were maintained on the FvB/N background. The
transgenic lines expressing either the cMyBP-CWT [21] or cMyBP-CΔCTS
[37] transgenes were crossed to the cMyBP-C(t/t) mouse line (cMyBP-
C(t/t)) [40–42] to study the eﬀect of the transgenic protein without
endogenous cMyBP-C (see discussion for further details). All procedures
followed the protocol approved by the Institutional Animal Care and
Use Committee of Loyola University Chicago and the University of
Cincinnati and complied with the Guide for the Use and Care of La-
boratory Animals published by the National Institutes of Health. All
biochemical and functional assays were performed on 8- to 12-week-old
mice of mixed sex with age- and sex-matched controls for each assay
after preliminary experiments showed no gender diﬀerences.
2.3. Assessment of in vivo cardiac function
Echocardiography measurements were made on 8- to 10-week-old
mice using a VisualSonics Vevo 2100 with an MS400 18–38MHz
transducer (FujiFilm, Toronto, Ontario) under 1% isoﬂurane anesthesia.
Cardiac function was measured from parasternal long axis M-mode
recordings as previously described [40,43]. Pressure-volume catheter-
ization was performed on anesthetized mice to determine cardiac he-
modynamics using a pressure-volume catheter (SPR-839; Millar In-
struments Inc., Houston, TX) on 8- to 12-week-old mice, as previously
described [44].
2.4. Induction of I/R injury
For mouse ischemia/reperfusion studies shown, the mice were an-
esthetized with a 90mg/kg pentobarbital injection delivered I.P. and
the chest was open through a left thoracotomy as previously described
[45]. Cardiac I/R injury was induced by ligation of the left anterior
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descending coronary artery for 60min of ischemia, followed by 24 h of
reperfusion in 8- to 10-week-old mice [22,45]. As a terminal procedure,
the mice were anesthetized with a second 90mg/kg pentobarbital in-
jection delivered I.P., followed by removal of the heart. The heart was
cannulated through the aorta and the heart was perfused with 1% tri-
phenyl tetrazolium chloride (TTC), as previously described [45,46].
This was followed by the re-occlusion of the coronary artery (suture
was left in place) and perfusion of the heart through the aorta of a 5%
Phthalo Blue Pigment solution (Heucotech); the occlusion was released
and hearts were rinsed and cut into cross-sectional slices, weighed and
photographed. The total area of the section, risk and non-risk regions as
delineated by TTC and blue stains were quantiﬁed for each section
using ImageJ software.
2.5. Cellular and molecular analyses
Histological analysis, electron microscopy, and immuno-
ﬂuorescence microscopy were performed, as described previously
[40,43]. Analysis of cMyBP-C and the phosphorylation status of S273,
S282, and S302 were performed by Western blot using custom-made
antibodies that recognize each residue only when phosphorylated. All
buﬀers used for isolating protein samples contained protease inhibitor
(Roche, 4693159001) and phosphatase inhibitor cocktails (Sigma
P5726, P0044). TaqMan primers were used to determine gene expres-
sion with probes recognizing Myh7 and Nppa normalized to Gapdh
(Applied Biosystems, Mm01319006g1; Mm01255748g1; 4352339E,
respectively). Probes and templates were used with iTaq Probes Master
Mix (BioRad 172-5131) and quantiﬁed using a BioRad CFX96 ther-
mocycler. Mybpc3 expression was measured using SybrGreen inter-
calating dye with forward 5′-ATATAGGCCGGGTCCACAA-3′ and re-
verse 5′-GCAACAACCACAATGGTGTC-3′ primers (208 bp amplicon)
normalized to Actb ampliﬁed with forward 5′-GGCTGTATTCCCCTCCA
TCG-3′ and reverse 5′-CCAGTTGGTAACAATGCCATGT-3′ (154 bp am-
plicon) primers. All qPCR data were analyzed using the 2−ΔΔCq method.
2.6. Assessment of calpain activity
Calpain activity was assessed using the Calpain-Glo Protease Assay
(Promega). In 96-well plates, 50 μl of blanks, control samples con-
taining puriﬁed μ-calpain (Calbiochem), or test samples were mixed
with 50 μl of Calpain-Glo™ reagent with 2mM CaCl2. Plates were agi-
tated for 30 s at 300–500 RPM followed by incubation at room tem-
perature for 5–30min. The plates were read using a luminometer, de-
tecting the luciferase signal generated following cleavage of the
Calpain-Glo™ reagent by calpain. To determine the eﬀects of calpain
activation on myoﬁlament proteolysis, calpain was inhibited in vitro
using 10 nM of the selective inhibitor MDL 28170 (EMD Biosciences, La
Jolla, CA) in 200mM imidazole, 20mM L-cysteine, and 10mM CaCl2 at
37 °C. The inhibitor was dissolved in dimethyl sulfoxide (DMSO) and
added to the perfusion buﬀer prior to heart perfusion at a concentration
of 10 μM.
2.7. Architectural analysis of the ventricular wall with generalized Q-space
MRI
The theory and methods of Q-space MRI (GQI) for imaging
myoarchitecture in human (in vivo) and rodent (ex vivo) models were
previously described [47,48]. Employing GQI, multiple gradient pulses
were applied with varying orientations and diﬀusion sensitivities to
evaluate signal attenuation in 3D space, employing a 7 Tesla Bruker
Biospec magnet equipped with a CryoProbe (Bruker Corp., Billerica,
MA). MR scanning was accomplished with a multi-shot EPI pulse se-
quence employing 512 gradient directions, B value of 750 s/mm2, 8 k-
space segments, and a voxel size of 100×100×300 μm. The resulting
GQI image was assessed to discern the orientation and magnitude of the
dominant ﬁber populations with the 3D directionality of the ﬁber po-
pulations encoded to a red-green-blue scale. Intervoxel ﬁber tracts were
constructed by employing streamline methods based on the alignment
of the maximal diﬀusion vectors embodied in the diﬀusional probability
Fig. 1. Cardiac MyBP-C is dephosphorylated and
degraded in ischemic human myocardium. (A)
Representative sample of human infarcted heart
tissue with annotated remote [R], border zone [B],
and ischemic regions [I]. (B) A representative
Coomassie blue-stained SDS-PAGE of myoﬁlament
protein preparations from the remote, border, and
ischemic regions of an ischemic human heart reveals
clear protein degradation in the ischemic region. (C)
Calpain protease activity measured in the remote,
border, and ischemic regions (n= 6). (D) Western
blotting with remote, border, and ischemic protein
samples shows full-length and degraded 40 kDa
cMyBP-C (top panel) and cMyBP-C phosphorylated
at residues S273, S282, and S302, with actin shown
as a loading control (bottom). (E) The relative per-
centage of full-length and degraded 40 kDa cMyBP-C
in the remote, border, and ischemic regions (n= 9;
# comparison of full-length cMyBP-C among tissue
regions, ‡ comparison of 40 kDa cMyBP-C among
tissue regions using one-way ANOVA with Holm-
Sidak post-hoc test). (F) Quantiﬁcation of phos-
phorylated S273, S282, and S302 normalized against
total full-length cMyBP-C (n=8, top; 4, middle; 6,
bottom). All data are mean ± SEM (* P < 0.05;
one-way ANOVA with Holm-Sidak post-hoc test).
(For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web ver-
sion of this article.)
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distribution function (pdf). Cardiac ﬁber orientation was analyzed for
helix angle as a function of depth of the myocardium sampled, as
previously described (33). In brief, regions of interest (ROI) were placed
at various depths across the ventricular wall, and helix-angle at speciﬁc
locations was quantiﬁed and plotted for each heart type. The relative
transmural depth (RTD) was calculated for each ROI in a sample using
the ratio of the number of ROI positions from the innermost tissue wall
divided by the total number of ROIs required to traverse the cardiac
wall. The RTD for each ROI in a sample was calculated and displayed as
a percentage of the cardiac wall distance.
2.8. Statistics
Statistical analysis was performed using GraphPad Prism 6. Data in
Figs. 1, 2, 4, 5, and S1 were analyzed by one-way ANOVA to determine
group diﬀerences. Following ANOVA, group diﬀerences were evaluated
by a Holm-Sidak post-hoc test. Signiﬁcance was deﬁned at p < 0.05.
Data in Fig. 7 were also analyzed with a two-tailed Student's t-test.
Statistical comparisons of transmural helix angles were performed
employing one-way ANOVA on a linear regression using least mean
squares.
3. Results
3.1. Calpain proteases are activated and cMyBP-C is degraded in infarcted
human hearts
To investigate the role of cMyBP-C proteolysis following ischemia,
we ﬁrst evaluated the active state of calpain and whether cMyBP-C is
degraded in human heart samples following MI. Using samples of in-
farcted human hearts, we isolated ischemic tissue, border zone tissue
adjacent to the infarct area, and tissue from an area remote from the
ischemic site (Fig. 1A). We also used non-ischemic human heart tissue
from unused donor hearts as controls. Myoﬁlament protein extractions
from the ischemic region exhibited general protein degradation com-
pared to remote and border tissues (Fig. 1B). Using a calpain activity
assay, we observed signiﬁcantly higher calpain activity in the border
zone and ischemic region compared to the remote area and control
donor hearts (Fig. 1C). Western blotting revealed a reduction in full-
length cMyBP-C and a concomitant increase in 40 kDa N′-terminal
cMyBP-C proteolysis in the border and infarct tissues compared to the
remote area (Fig. 1D and E). Dephosphorylation of residues S273, S282,
and S302 is a required step that precedes cMyBP-C proteolysis and
generation of the 40 kDa fragment, as previously reported [14,33].
Using antibodies that detect the phosphorylated epitope of these re-
sidues, we observed decreased phosphorylation of cMyBP-C in human
ischemic tissue compared to remote or border tissues (Fig. 1F).
3.2. I/R injury is associated with increased calpain activity and cMyBP-C
proteolysis in mice
I/R injury or sham surgery was performed on non-transgenic (NTG)
wild-type mice, and tissue from ischemic, border zone, and remote
myocardium was identiﬁed with Phthalo Blue Pigment and TTC
staining (Fig. 2A). Total protein lysates from these regions were as-
sessed for full-length and degraded α-fodrin, a known substrate of
calpain proteases [49]. An increase of the 145 kDa α-fodrin proteolysis
product was identiﬁed in border zone and ischemic tissues compared to
sham and remote samples (Fig. 2B). Calpain activity was signiﬁcantly
elevated in border and infarcted tissues compared to remote and sham
tissue controls (Fig. 2C). Levels of total cMyBP-C, 40 kDa cMyBP-C, and
phosphorylated cMyBP-C were assessed by Western blot (Fig. 2D). Full-
length cMyBP-C was reduced in border and ischemic tissues compared
to sham and remote samples (Fig. 2E). Levels of phosphorylated cMyBP-
C residues normalized to total cMyBP-C revealed a signiﬁcant reduction
of phosphorylated S273 and S282 in ischemic tissue only (Fig. 2F-H).
3.3. Calpain proteases degrade cMyBP-C and generate a 40 kDa fragment
In silico analysis [50] of the cMyBP-C amino acid sequence identiﬁed
a candidate CTS with proteolysis expected between residue R271 and
T272 (Fig. 3A). The CTS includes residues 272-TSLAGAGRR-280 and is
consistent with the previously determined sequence of the 40 kDa N′-
terminal fragment that contains cMyBP-C residues 1–271 [50]. To
Fig. 2. Cardiac MyBP-C is dephosphorylated and
degraded in a mouse ischemia/reperfusion model.
(A) TTC-staining of I/R-injured mouse hearts showed
the remote regions stained blue [R], the border re-
gion stained pink [B], and the infarct [I] region in
white. The sham heart [S] was stained with TTC and
blue dye and shows uniform blue staining. (B) The
calpain proteolysis target α-fodrin shows degrada-
tion in protein samples from the border and ischemic
regions. (C) Calpain activity was determined from
sham, remote, border, and infarcted regions (n= 6,
S; 6, R; 7, B; 7, I). (D) The levels of cMyBP-C from
these regions were determined using Western blot
with the anti-cMyBP-C2–14 antibody, and the extent
of cMyBP-C degradation was evaluated. The pre-
sence of the 40 kDa cMyBP-C N′-terminal fragment
was identiﬁed in the remote and infarct area.
Sarcomeric actin was used as a loading control
(lower panel). Western blot analysis of cMyBP-C was
performed to determine the level of cMyBP-C phos-
phorylation using phospho-speciﬁc antibodies. (E)
Quantiﬁcation of total cMyBP-C and (F-H) phos-
phorylated cMyBP-C at residues S273, S282, and
S302 (n= 6, total protein; 4, phospho-protein). All
data are mean ± SEM (* P < 0.05; one-way
ANOVA with Holm-Sidak post-hoc test). (For inter-
pretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of
this article.)
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establish cMyBP-C as a calpain substrate, we incubated 20 μg of myo-
ﬁlament protein from wild-type mouse hearts with increasing con-
centrations of μ-calpain at 37 °C for 1 h with 10mM calcium. The results
demonstrated a dose-dependent increase in the proteolysis of full-
length cMyBP-C and generation of the 40 kDa fragment (Fig. 3B). To
further demonstrate the speciﬁc calpain-mediated degradation of
cMyBP-C, we incubated myoﬁlament proteins with 1 μg calpain in the
presence and absence of 10mM calcium and with 10 nM of the calpain
inhibitor MDL 28170. In the presence of calcium, calpain could degrade
cMyBP-C, whereas removal of calcium from the buﬀer or inclusion of
MDL 28170 prevented the generation of the 40 kDa cMyBP-C proteo-
lytic fragment (Fig. 3C). In order to compare calpain-mediated pro-
teolysis of cMyBP-C and other known myoﬁlament calpain substrates,
1 U of μ-calpain was incubated with 20 μg of myoﬁlament protein for
diﬀerent durations with 10mM calcium. Digested proteins were re-
solved using 4–15% SDS-PAGE that revealed protein degradation after
12 h of calpain treatment (Fig. 3D). Western blot analysis using anti-
cMyBP-C2–14 antibodies showed a reduction in full-length cMyBP-C at
12 h of incubation with a corresponding rise in the 40 kDa N′-terminal
fragment (Fig. 3E). Cardiac troponin T and troponin I are known targets
of calpain proteolysis [13,51]. Western blotting for these troponins
revealed similar proteolytic activity in both troponins and an increased
amount of troponin proteolytic fragments with increasing calpain in-
cubation time (Fig. 3F and G). These results conﬁrm that calpain
cleaves cMyBP-C into multiple fragments, principally including a
40 kDa fragment.
3.4. Transgenic mouse model with ablation of the CTS in cMyBP-C has
normal levels and preserved phosphorylation of cMyBP-C
Previous investigations using transgenic mice with residues S273,
S282, and S302 mutated to phosphomimetic aspartic acids were re-
sistant to proteolysis of cMyBP-C and had signiﬁcant improvement of
cardiac function following ischemia [22]. Conversely, depho-
sphorylation has been associated with increased cMyBP-C proteolysis
following ischemic injury [35]. These data led us to investigate whether
abrogation of calpain-mediated proteolysis of full-length cMyBP-C
would be suﬃcient to confer the previously observed phosphorylation-
mediated cardioprotection. To test this question, we used a transgenic
mouse with a deletion of the cMyBP-C CTS (residues 272-TSLAGA-
GRR-280) [35], termed as ΔCTS [37]. This transgenic cMyBP-C ΔCTS
construct includes an N′-terminal Myc tag and a Myh6 promoter for
cardiac-speciﬁc expression (Fig. 4A). This construct was expressed in
the cMyBP-C(t/t) mouse line that does not express endogenous cMyBP-
C and normally has profound dilation and systolic dysfunction [41–43].
In order to control for transgenic overexpression of cMyBP-C, an ad-
ditional transgenic mouse line was used that expresses full-length wild-
type cMyBP-C with an N′-terminal Myc tag driven by the Myh6 pro-
moter [21]. This, too, was expressed in the cMyBP-C(t/t) background
and is referred to as WT(t/t). A further description of the cMyBP-C(t/t)
and transgenic mouse models of cMyBP-C is included in the discussion.
Deletion of the CTS residues 272-TSLAGAGRR-280 removes S273,
although the amino acid sequence immediately preceding S282 remains
largely unaltered (Fig. 4A). These phosphorylation sites are critical for
regulating cardiac function [27]. To assess potential cardiac hyper-
trophy following CTS deletion, we evaluated the heart weight-to-body
weight ratio, which showed no diﬀerences among non-transgenic
(NTG), WT(t/t), and ΔCTS(t/t), but with a signiﬁcant increase in the t/t
group (Fig. 4B and C). Expression of the hypertrophic markers Nppa and
Myh7 was signiﬁcantly elevated in t/t samples compared to NTG, but
with no elevation observed in WT(t/t) or ΔCTS(t/t) (Fig. 4D and E).
Separation of α- and β-myosin heavy chain proteins using 6% glycerol
SDS-PAGE and visualized with SYPRO Ruby staining showed an in-
crease of the hypertrophic marker β-myosin heavy chain in the t/t
group, again with no diﬀerences among NTG, WT(t/t), and ΔCTS(t/t)
(Fig. 4F).
Expression of the Mybpc3 transcript shows transgenic over-
expression in both WT(t/t) and ΔCTS(t/t) groups (Fig. 4G). Myoﬁla-
ment protein isolation from NTG, t/t, WT(t/t), and ΔCTS(t/t) hearts
resolved with SDS-PAGE and visualized with SYPRO Ruby showed
normal stoichiometry of cMyBP-C and other myoﬁlament proteins be-
tween mouse lines, excepting the t/t group that does not express de-
tectable levels of cMyBP-C (Fig. 4H). Western blotting of whole-heart
protein lysates for cMyBP-C showed normal protein levels between the
NTG, WT(t/t), and ΔCTS(t/t) groups, conﬁrming that cMyBP-C stoi-
chiometry is not altered by transgenic overexpression, whereas no
Fig. 3. Calpain proteases degrade cMyBP-C and generate the
40 kDa fragment. (A) In silico analysis of calpain proteolysis
sites on cMyBP-C, with bar height representing the likelihood
of cleavage, indicates R271 as a potential location of cleavage
(dotted line), corresponding to the known sequence of the
40 kDa fragment. The calpain-target site is highlighted in
black. (B) Incubation of myoﬁlaments with increasing con-
centration of calpain with 10mM calcium for 1 h at 37 °C
shows a dose-dependent increase in cMyBP-C proteolysis and
the generation of the 40 kDa fragment with a SYPRO Ruby-
stained SDS-PAGE loading control (bottom). (C) Proteolysis of
cMyBP-C in myoﬁlament fractions incubated with 1 μg cal-
pain for 1 h at 37 °C is prevented in the absence of calcium or
in the presence of 10 nM of the calpain inhibitor MDL 28170.
(D) Myoﬁlament protein fractions demonstrate proteolysis at
time points following incubation of 20 μg of total myoﬁlament
protein with 1 U μ-calpain with 10mM calcium. (E) Western
blotting for cMyBP-C shows reduction in full-length cMyBP-C
and an increase in 40 kDa cMyBP-C with longer calpain in-
cubation. (F and G) The known calpain targets cTnT and cTnI
show a reduction in full-length protein and an increase in
degraded protein with increasing incubation time with cal-
pain.
D.Y. Bareﬁeld, et al. Journal of Molecular and Cellular Cardiology 129 (2019) 236–246
240
cMyBP-C was detected in the (t/t) group (Fig. 4I). To evaluate how the
loss of CTS aﬀects the phosphorylation of cMyBP-C, two-colour ﬂuor-
escent Western blots were performed to detect total and phosphorylated
cMyBP-C and S273, S282, and S302 (Fig. 4J). Quantiﬁcation of phos-
phorylated cMyBP-C showed that the phosphorylated S273 epitope was
lost in the ΔCTS(t/t) group, but with no signiﬁcant diﬀerences between
NTG and WT(t/t) (Fig. 4K). Phosphorylation of S282 was not diﬀerent
between groups, whereas S302 phosphorylation showed a signiﬁcant
increase in the WT(t/t) and ΔCTS(t/t) groups compared to NTG
(Fig. 4L, M). Taken together, these data demonstrate that the loss of
cMyBP-C CTS does not result in overt cardiac pathology or alter normal
cMyBP-C protein levels. Importantly, the deletion of CTS does not alter
phosphorylation of the functionally critical S282 residue [27].
3.5. Loss of the calpain target site does not alter gross cardiac morphology
Morphological analysis of the ΔCTS(t/t) model was performed to
assess the consequences of the change in the protein sequence.
Myocardial sections were stained with hematoxylin & eosin or Masson's
trichrome to detect ﬁbrosis (Fig. S1A). Staining revealed increased ﬁ-
brosis in the t/t group, but no abnormalities among NTG, WT(t/t), and
ΔCTS(t/t) hearts. Electron microscopy images of cardiac sarcomeres
revealed normal M-line structure and proper orientation in NTG, WT(t/
t), and ΔCTS(t/t) samples, while t/t sarcomeres showed disarray and
improper M-line arrangement (Fig. S1B). Immunoﬂuorescence micro-
scopy performed on isolated cardiomyocytes showed typical cMyBP-C
(green) C-zone doublet patterning between the α-actinin (red)-stained
Z-disks (left panel) (Fig. S2A); no cMyBP-C was observed in the t/t
samples. Anti-Myc antibodies were used to detect Myc-tagged WT and
CTS transgenic protein constructs (green) (Fig. S2B). NTG and t/t
groups showed no Myc staining, but WT(t/t) and ΔCTS(t/t) showed
Myc doublet staining (green) between the α-actinin (red)-stained Z-
disks, which is consistent with proper cMyBP-C localization. The
myoarchitecture of the left ventricular wall, as represented by the
transmural helix angle transition (Fig. S3), was well preserved in the
ΔCTS(t/t) mouse hearts (Fig. 5A and B) compared with WT(t/t) mouse
hearts and previously published myoarchitectural studies [47,48].
3.6. ΔCTS(t/t) mice show normal cardiac function
M-mode echocardiography did not show changes in wall thickness
or left ventricular diameter in the ΔCTS(t/t) mice compared to NTG or
WT(t/t) (Fig. 6A and B, Table S1). No signiﬁcant change in % fractional
shortening was measured among NTG, WT(t/t), and ΔCTS(t/t) in con-
trast to the signiﬁcantly reduced systolic function and chamber dilation
in the t/t group (Fig. 6B-D). Ejection fraction measured directly by left
Fig. 4. Transgenic expression of cMyBP-C with ablation of the CTS. (A) Schematic representation of the transgenic cMyBP-C construct which includes an α-myosin
heavy chain promoter, N′-terminal Myc tag sequence, Mybpc3 cDNA, and an hGh polyadenylation site. The ΔCTS construct removes the region coding for CTS, amino
acids 272-TSLAGAGRR-280. (B and C) HW:BW ratios showed cardiac hypertrophy in the t/t hearts, with no changes observed in WT(t/t) or ΔCTS(t/t) compared to
NTG (n= 8, 8, 7, 8). (D and E) Expression of the hypertrophic markers Nppa andMyh7 normalized to Gapdh by qPCR showed a signiﬁcant elevation in the t/t samples
only (n=3). (F) Separation of myosin heavy chain isoforms by SDS-PAGE to identify the hypertrophic marker β-myosin heavy chain showed an increase in the t/t
group only. (G) The expression level of totalMybpc3 transcript normalized to Actb by qPCR shows transgenic overexpression in the WT(t/t) and ΔCTS(t/t) hearts. (H)
Myoﬁlament protein fractions from NTG, t/t, WT(t/t), and ΔCTS(t/t) hearts resolved by SDS-PAGE and stained with SYPRO-Ruby showed no changes in cMyBP-C
stoichiometry. (I) Western blotting of cMyBP-C from whole-heart lysate reveals normal cMyBP-C stoichiometry in the WT and ΔCTS hearts compared to NTG with no
detectable cMyBP-C in the t/t hearts. (J) Two-colour ﬂuorescent Western blots of total and phospho-serine cMyBP-C. (K-M) Quantiﬁcation of phosphorylated cMyBP-
C at residues 273, 282, and 302 (n= 4). All data are mean ± SEM (* P < 0.05 vs. NTG, ‡ P < 0.05 vs. t/t, # P < 0.05 vs. WT(t/t); one-way ANOVA with Holm-
Sidak post-hoc test).
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ventricular pressure-volume catheterization revealed a similar pattern
with a signiﬁcant reduction in systolic function only in the t/t group
(Fig. 6I). The left ventricular volumes at end systole and end diastole
were signiﬁcantly increased only in the t/t hearts, which is consistent
with the dilated phenotype associated with this mouse model (Fig. 6H).
Preload recruitable stroke work was signiﬁcantly decreased only in the
t/t group, indicating impaired contractility (Fig. 6G). Diastolic function
measured as the time to relaxation (τ-Weiss) was also signiﬁcantly
slower only in the t/t mice (Fig. 6J). These data, combined with normal
protein levels, protein localization, and cardiac morphology, suggest
that the ΔCTS(t/t) mouse is functionally indistinguishable from the
NTG and WT(t/t) controls under normal conditions.
3.7. Ablation of the CTS of cMyBP-C prevents calpain proteolysis and is
cardioprotective following I/R injury
To directly assess whether the ΔCTS cMyBP-C is, in fact, resistant to
calpain proteolysis, we incubated myoﬁlament protein extracted from
NTG, WT(t/t), and ΔCTS(t/t) hearts with μ-calpain. NTG myoﬁlament
samples treated with μ-calpain showed proteolysis of cMyBP-C with the
appearance of the N′-terminal 40 kDa fragment, whereas calpain
treatment of ΔCTS(t/t) samples did not produce any detectable cMyBP-
C proteolysis (Fig. 7A and B). To determine if ablation of the CTS is
protective following ischemic injury, NTG, WT(t/t), and ΔCTS(t/t) mice
were subjected to 60min of ischemia followed by 24 h of reperfusion.
Echocardiography was performed pre- and post-ischemia to assess
changes in cardiac function. ΔCTS(t/t) animals showed preserved sys-
tolic function, with no signiﬁcant reduction in % fractional shortening
following ischemia (Fig. 7C, Table S2). Following ischemia, heart
samples were stained with TTC and Phthalo Blue Pigment solution to
identify the infarct area and the area at risk (Fig. 7D). Quantiﬁcation of
Fig. 5. Normal cardiac transmural ﬁber helical progression in CTS(t/t) hearts
compared to NTG, WT(t/t), and t/t ascertained by generalized Q-space MRI
(GQI) with tractography. (A) Quantiﬁcation of CTS helical transmural ﬁber
progression with individual readings (points), mean readings at each location
(grey line) and the 95% conﬁdence interval (black lines) shown as the function
of relative transmural depth (RTD) in the myocardium from endocardium to
epicardium (Endo:Epi) (n=4 hearts). (B) Transmural helix angle ﬁber pro-
gression shown as the linear regression of mean values for the NTG, t/t, WT(t/
t), and CTS(t/t) hearts shown as the function of the relative transmural depth in
the myocardium. The (t/t) demonstrates signiﬁcantly reduced helix angle
progression compared to all other groups, which indicates a pathological ar-
chitectural phenotype. (* P < 0.05 compared to NTG, ‡ P < 0.05 compared to
t/t; one-way ANOVA on linear regression model with least squared means).
Fig. 6. Transgenic expression of ΔCTS in the t/t background shows normal
cardiac structure and function. (A-C) Representative parasternal long axis M-
mode echocardiography images showed dilation and reduced contractility only
in the t/t hearts (n= 6, 6, 4, 7). (D) Representative pressure-volume loops. (E)
Pressure-volume catheterization derived ejection fraction, (F) end diastolic
volumes, (G) contractility shown by preload recruitable stroke work (PRSW),
and (H) relaxation (Tau) were not signiﬁcantly diﬀerent in WT(t/t) and ΔCTS(t/
t) compared to NTG, whereas deﬁcits were observed in t/t hearts across all
parameters (n=6, 6, 6, 7). All data are mean ± SEM (* P < 0.05 vs. NTG, ‡
P < 0.05 vs. t/t; one-way ANOVA with Holm-Sidak post-hoc test).
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the area at risk showed that the extent of ischemia was not signiﬁcantly
diﬀerent between NTG, WT(t/t), and ΔCTS(t/t) hearts, indicating that
all groups received a similar surgical insult (Fig. 7E). However, the
infarct area was signiﬁcantly reduced in the ΔCTS(t/t) hearts compared
to NTG, whereas WT(t/t) infarct area was not signiﬁcantly reduced
compared to NTG (Fig. 7F). This result was recapitulated using a se-
parate set of I/R surgeries on NTG and ΔCTS(t/t) mice under the same
conditions at a separate institution (Fig. S4).
4. Discussion
Myocardial dysfunction is a clinically important consequence of
myocardial ischemia or infarction [1]. Impairments in calcium hand-
ling, contractile protein phosphorylation, and sarcomere integrity often
accompany contractile dysfunction, but the subcellular mechanisms
responsible for these deﬁcits remain incompletely deﬁned [13,51].
Phosphorylation of cMyBP-C has a direct eﬀect on the heart's con-
tractile properties, as well as sarcomere organization, and contributes
to cardioprotection during I/R injury [15,17,22]. Cardiac MyBP-C de-
gradation during I/R injury may contribute to sarcomere disorganiza-
tion and contractile dysfunction in the recovering myocardium [14,34].
4.1. Animal models of cMyBP-C
Many studies have used mouse models of cMyBP-C to establish the
involvement of cMyBP-C in cardioprotection during ischemic injury. As
in previous studies, we have used transgenic models of cMyBP-C ex-
pressed on the cMyBP-C t/t background to evaluate the function of
transgenic cMyBP-C constructs without confounding eﬀects from
endogenous cMyBP-C. The cMyBP-C t/t model was engineered to have
a truncating stop site inserted in exon 30 to model a human mutation
with a similar truncation [42]. When the cMyBP-C t/t model was ori-
ginally reported by McConnell et al. (1999), Western blot data showed
a substantial amount of cMyBP-C in the t/t hearts [42]. However, in
numerous subsequent reports by several research groups using this
mouse line, no cMyBP-C protein has been detected by Western blot or
immunoﬂuorescence microscopy, using several high-quality antibodies
[21,43,52]. While this discrepancy has never been explained, the pos-
sibility remains that undetectable levels of mutant cMyBP-C could cause
alterations in cardiac function. This possibility appears unlikely based
on the evidence that models expressing various transgenic cMyBP-C
constructs on the t/t background do not share the t/t model's pathology,
despite rigorous cardiac phenotyping [21,22,40].
Transgenic cMyBP-C constructs have been used to elucidate the
functions of phosphorylatable residues in the cMyBP-C M-domain
[21,22,27,53], and in these studies, transgenic overexpression of WT
cMyBP-C on the t/t background has never been shown to be sig-
niﬁcantly diﬀerent from NTG controls at baseline or after I/R injury.
Diﬀerential phosphorylation of the three major serines, S273, S282, and
S302, alter the ability of cMyBP-C to regulate cross-bridge cycling [17].
The deletion of CTS results in loss of the S273 site and alteration of
residues near S282. Phosphorylation of S282 is critical for subsequent
S302 phosphorylation and regulation of myoﬁlament function [27];
therefore, evidence that S282 can still be phosphorylated after the loss
of CTS is likely critical for the absence of any functional deﬁcits in this
model.
Fig. 7. Prevention of calpain proteolysis of cMyBP-C reduces infarct size following ischemia-reperfusion injury. (A) Western blot of cMyBP-C from NTG, WT(t/t), and
ΔCTS(t/t) myoﬁlaments incubated with and without calpain in 1.25mM calcium shows the generation of the N′-terminal 40 kDa cMyBP-C proteolysis fragment. The
fragment appears at a higher weight in the WT(t/t) sample due to the presence of a Myc tag. (B) Quantiﬁcation of the percent of 40 kDa cMyBP-C fragment to total
cMyBP-C (n=3) (* P < 0.05; two-way ANOVA). (C) Echocardiography results from NTG, WT(t/t), and ΔCTS(t/t) mice pre- and post-I/R show preserved systolic
function in ΔCTS(t/t) mice but not in NTG or WT(t/t) controls. Additionally, NTG and WT(t/t) hearts showed ventricular wall thinning following I/R, whereas this
was not apparent in ΔCTS(t/t) hearts (n= 5) (horizontal black bars represent p < 0.05 between indicated groups; two-way ANOVA). (D) Example tissue sections of
NTG, WT(t/t), and ΔCTS(t/t) hearts stained with TTC and Phthalo Blue pigment solution following I/R injury. After cutting into cross sections, tissue mass, area at
risk, and infarct areas were measured. Blue myocardium represents the remote area, red stained myocardium represents the area-at-risk, and the white regions are
infarcted tissue. (E) Quantiﬁcation of these areas show the area at risk was similar between the three groups. (F) The % infarct area was signiﬁcantly reduced in ΔCTS
(t/t) hearts. (n=5, NTG; 6, WT(t/t); 6, ΔCTS(t/t)). Horizontal black bar represents p < 0.05 between indicated groups; one-way ANOVA). All data are
mean ± SEM. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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4.2. Calpain proteolysis of myoﬁlament proteins
During cardiac ischemia, increased intracellular calcium activates
calpain proteases [51,54,55], resulting in the degradation of myoﬁla-
ment proteins [56,57]. This proteolysis regulates physiological myoﬁ-
lament turnover [58] and hypertrophic remodeling during cardiac
stress [59]. Inactive calpains localize to the myoﬁlament Z-disk under
normal physiological conditions, emphasizing their importance in
myoﬁlament proteolysis [60]. Calpain proteolysis precedes the release
of cardiac troponin fragments into the circulation following ischemic
injury, and measurement of these fragments is the current gold standard
for clinical diagnosis of myocardial ischemia [61,62]. Experimental
methods have long used calpains to isolate speciﬁc myoﬁlament com-
ponents and have shown that these calcium-dependent, nonlysosomal
cysteine proteases can degrade cMyBP-C [28]. Observations of cMyBP-
C proteolysis in ischemic tissue have suggested calpain as the protease
principally responsible for generating the 40 kDa cMyBP-C fragment
[14,35]. We have now identiﬁed the exact location of calpain cleavage
that contributes to cMyBP-C proteolysis and that it generates the pre-
viously identiﬁed 40 kDa N′-terminal fragment. Future studies will
evaluate the eﬀects of calpain proteolysis in vivo in the ΔCTS(t/t) during
ischemia.
4.3. Regulation of cMyBP-C by proteolysis
Identiﬁcation of this 40 kDa N′-terminal fragment of cMyBP-C in
ischemic myocardium was performed by using cMyBP-C N′-terminal
antibodies [34,35]. Viral expression of the 40 kDa cMyBP-C fragment in
adult rat cardiomyocytes and addition of the recombinant 40 kDa
fragment into permeabilized human cardiomyocytes have both resulted
in impaired myoﬁlament contractile function [14,36]. In addition, the
proteolysis of cMyBP-C removes the N′-terminal domains from their
functional location in the myoﬁlament where these domains normally
regulate actomyosin interactions [28]. Systemic release of cMyBP-C
fragments causes an acute inﬂammatory response that may provide
further insult to the heart during reperfusion [63]. The known cytotoxic
eﬀects of cMyBP-C proteolysis and the observed reduction in infarct
size in ΔCTS(t/t) mouse hearts following ischemic injury suggest that
degradation of cMyBP-C may not only occur as a result of ischemic
signaling events but can potentially exacerbate the progression of cell
death within the ischemic myocardium [34].
The calpain proteolysis site is located within the phosphorylatable
M-domain of cMyBP-C. Colocalization of these sites suggests a reg-
ulatory interaction between the phosphorylation status of cMyBP-C and
its degradation. A mouse line expressing a phospho-mimetic cMyBP-C
transgene in which phosphorylatable sites S273, S282, and S302 were
mutated to aspartic acid mitigates cMyBP-C degradation [22]. These
mice exhibit cardioprotection during I/R injury similar to that observed
from ischemic preconditioning and to an extent similar to that observed
in the current study. This stands in contrast to cMyBP-C proteolysis that
occurs with reduced cMyBP-C phosphorylation levels following hypoxia
[35]. Accordingly, we have hypothesized that phosphorylation of
cMyBP-C inhibits the ability of calpain to degrade cMyBP-C within the
phosphorylatable M-domain. This could explain how cMyBP-C phos-
phorylation prevents cMyBP-C proteolysis to confer cardioprotection
following ischemia [21,22]; although whether cMyBP-C phosphoryla-
tion prevents calpain proteolysis by altering the recognition site or
sterically inhibiting the enzyme remain to be determined. While the
myocardial tissue response to ischemia is multi-faceted, embodying
spatially distributed patterns of apoptosis [10–12], hypoxia [8,9], and
ﬁbrogenesis [4–7], our current ﬁndings provide evidence that calpain-
mediated cMyBP-C proteolysis is a pivotal event in the injury sequence
occurring in vivo.
5. Conclusions
We assessed whether the abrogation of calpain-directed degradation
of cMyBP-C is responsible for cardioprotection by ablating the calpain-
target sequence in cMyBP-C and assessing the eﬀect on infarct size.
Ablation of the CTS site in the phosphorylatable M-domain of cMyBP-C
was associated with signiﬁcantly reduced infarct size following I/R
injury. These ﬁndings support the beneﬁcial eﬀect of stabilizing cMyBP-
C during ischemia to preserve myocardial function in reperfused tissue.
Previous eﬀorts to explain cMyBP-C phosphorylation-mediated cardio-
protection have focused on the importance of preserving cMyBP-C
phosphorylation and the role of phosphorylation in altering myoﬁla-
ment contractility as the mechanism of cardioprotection. By demon-
strating that cardioprotection occurs through the prevention of calpain-
mediated cMyBP-C proteolysis, even in the absence of direct manip-
ulation of cMyBP-C phosphorylation, we provide a rationale for a re-
newed investigation into calpain and the CTS as therapeutic targets and
the resultant regulation of calpain proteolysis during and after ischemic
injury.
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